Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue
Corcept Therapeutics (CORT) reported Q3 2026 revenue of $340.5M, up 64% YoY and 1.9% above estimates. EPS of $1.01 beat estimates by 27.2%. The company reconfirmed its full-year revenue guidance of $1.15B. Operating margin improved to 33.7% YoY. CEO highlights growth in endocrinology and ovarian cancer treatments.
How this was made
The 30-second read
Why it matters
The earnings beat was modest and guidance unchanged, leading to a 5% post‑earnings sell‑off, indicating short‑term downside pressure.
Market read
First‑report earnings release for a mid‑cap biotech with modest beat and unchanged guidance; immediate price impact observed.
What to watch
Rapid uptake of Lifyorli in ovarian cancer and growing endocrinology business may drive future top‑line growth beyond current guidance.
Background
Corcept Therapeutics (NASDAQ:CORT) posted Q3 2026 results, beating revenue and EPS estimates, reaffirming full‑year guidance, and noting strong product uptake.
Ticker impact
Corcept Therapeutics reported Q3 2026 revenue of $340.5M beating estimates and EPS of $1.01 beating consensus, with guidance unchanged.
likely pressure as the market prices in the modest guidance and the immediate 5% sell‑off.
The beat was modest and guidance unchanged, while the stock dropped 5% after the release, suggesting short‑term downside.
Market effects
Strong earnings beat may lift peer biotech stocks, but modest guidance could temper sector enthusiasm.
US biotech sector sees mixed reaction; limited broader market effect.
Limited to investors focused on US‑listed biopharma names.
Counterpoint
Despite the beat, the unchanged guidance and 5% price drop could present a buying opportunity if the market overreacts.
Key entities
- companyCorcept Therapeutics
Biopharma company reporting Q3 2026 earnings.
- personJoseph K. Belanoff, MD
CEO of Corcept who commented on growth.
